Twin Cretin
Twincretin is a dual-incretin research blend that acts on both the GLP-1 and GIP receptor pathways in a single once-weekly subcutaneous injection. It is studied for its effects on appetite regulation, satiety, gastric emptying, and glucose-dependent insulin signaling. It is used strictly in a research context and requires conservative weekly titration.
Research subjects exploring dual-incretin metabolic and appetite pathways who can commit to slow, tolerance-guided weekly titration under physician guidance.
Twincretin belongs to the dual-incretin class that co-activates the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, modeled on the tirzepatide pharmacology first described in the SURPASS and SURMOUNT clinical programs. Structurally these are single synthetic peptides engineered with a fatty-acid moiety that binds albumin, extending the circulating half-life to roughly five days and enabling once-weekly dosing. Mechanistically, GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying, while GIP receptor activation is thought to further augment insulin response and modulate central appetite and energy-handling pathways.
Research on the reference dual agonist has reported substantial reductions in appetite, body weight, and HbA1c relative to single GLP-1 agonism, with weight effects appearing even at low starting doses. The dose is titrated slowly precisely because the gastrointestinal system needs weeks to adapt; rapid escalation drives nausea and vomiting. Importantly, a research blend is not the FDA-approved branded product and may vary in identity, purity, and content; it is not approved for any therapeutic use and is provided for research use only.
Anyone considering it should do so with qualified physician oversight, appropriate monitoring, and an understanding that safety and efficacy of the specific blend have not been independently established. This information is educational and is not medical advice.
Subcutaneous, once weekly. A conservative research starting dose is 2.5 mg weekly for the first ~4 weeks (an adaptation dose), increasing by one step no sooner than every 4 weeks as tolerated across a common 2.5-15 mg range; the 2.5 mg start is the most conservative documented value and is meant for GI adaptation, not effect.
Appetite and satiety changes are often noticed within the first 1-2 weeks, with metabolic effects accumulating over several weeks of titration.
Typically run standalone; not stacked with other GLP-1 or GIP agonists due to overlapping mechanism and additive GI burden.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.